Printer Friendly

PARACELSIAN REPORTS FIRST QUARTER RESULTS

 ITHACA, N.Y., Feb. 26 /PRNewswire/ -- Paracelsian, Inc. (NASDAQ: PRLN), a developer of proprietary tests for the identification of cancer causing chemicals, today reported results for the first quarter ended Dec. 31, 1992.
 For the first three months of fiscal 1993, the company sustained a net loss of $528,123 or 22 cents per share compared to a net loss of $146,400 or 11 cents per share for the same period last year. The company had no operating revenues during the periods.
 "This loss reflected an acceleration of development activities geared to product introduction and the generation of revenues before the end of this fiscal year," Dr. John G. Babish, chairman, president and chief executive officer, said. "The validation process for our cell proliferation assay is proceeding on schedule," he concluded.
 PARACELSIAN, INC.
 Financial Highlights (Unaudited)
 Three months ended Dec. 31 1992 1991
 Sales -- --
 Net (loss) ($528,123) ($146,400)
 Net (loss) per share ($.22) ($.11)
 Weighted average shares outstanding 2,371,549 1,284,888
 -0- 2/26/93
 /CONTACT: Mary Lee Noden of Paracelsian, 607-272-7605/
 (PRLN)


CO: Paracelsian, Inc. ST: New York IN: MTC SU: ERN

PS-CK -- NY020 -- 0797 02/26/93 10:52 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 26, 1993
Words:198
Previous Article:DNA PLANT TECHNOLOGY REPORTS FOURTH QUARTER AND FULL YEAR RESULTS
Next Article:WASHINGTON HOMES 3 MILLION SHARE INITIAL PUBLIC OFFERING PRICED AT $9 PER SHARE
Topics:


Related Articles
PARACELSIAN INC. ACQUIRES PACIFIC LIAISONS
PARACELSIAN ELECTS T. COLIN CAMPBELL TO THE BOARD OF DIRECTORS; RENOWNED BIOCHEMIST, LECTURER AND AUTHOR
PN27,1 Safety Study Follow-Up Produces Continuing Favorable Results for Patients
Paracelsian Inc. and East West Herbs Ltd. Sign Sales, Marketing and Manufacturing Agreement
Paracelsian Inc. Reports Third-Quarter Results; $1.33 Million Cash On Hand
/C O R R E C T I O N -- Paracelsian, Inc./(Correction Notice)
Paracelsian patents approved for HIV treatment and cancer screen
Paracelsian Announces Receipt of Initial BioFIT(TM) Revenues from R.P. Scherer.
Paracelsian Announces Patent Approval & Kit Orders.
Paracelsian Announces Patent Issuance, and EPA Testimony.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters